Corona Remedies, founded in 2004 and headquartered in Ahmedabad, Gujarat, is a pharmaceutical company engaged in the research, manufacturing, and marketing of healthcare products. The company offers a range of products across multiple therapeutic areas, including women’s healthcare, cardio-diabetes, pain management, urology, and more. With two manufacturing facilities located in Gujarat and Himachal Pradesh, Corona Remedies has established a significant presence in the Indian pharmaceutical market. The company’s growth strategy includes organic expansion and strategic acquisitions, aiming to enhance its product portfolio and market reach. Corona Remedies continues to focus on delivering quality healthcare solutions to meet the evolving needs of patients.
IPO schedule
Issue open date
2025-12-08
Issue close date
2025-12-10
UPI mandate deadline
2025-12-10 (5 PM)
Allotment finalization
2025-12-11
Refund initiation
2025-12-12
Share credit
2025-12-12
Listing date
2025-12-15
Mandate end date
2025-12-25
Lock-in end date for anchor investors (50%)
2026-01-10
Lock-in end date for anchor investors (remaining)
2026-03-11
Financials
Financial Year Ended
March 2024
March 2025
June 2025
Total Assets
830.576
929.86
1012.38
Revenue
1020.931
1202.35
348.56
Profit After Tax
90.503
149.43
46.20
Issue size
Funds Raised in the IPO
Amount
Total issue size
655.37
Offer for sale - Proceeds go to the existing investors
655.37
Strengths
Consistent revenue growth with a CAGR of approximately 21% over the last three years.
Diversified product portfolio across multiple therapeutic areas.
Strong distribution network with a presence in urban and semi-urban areas.
Leadership positions in specific therapeutic segments, such as women’s healthcare and pain management.
EU-GMP and WHO-certified manufacturing facilities ensure high-quality production standards
Risks
High working capital intensity with a gross operating cycle exceeding 150 days.
Exposure to regulatory risks inherent in the pharmaceutical industry.
Dependence on contract manufacturing for certain products.
Ongoing capital expenditure projects with associated completion and cost risks.
Presence in a competitive and price-controlled domestic pharmaceutical market.